"DHAT Research Institute, a division of Digestive Health Associates of Texas, brings the future of gastroenterology medicine to Adults and Pediatrics in the Dallas-Fort Worth area. We strive to provide all patients, current and new, with access to cutting edge treatments prior to them being granted FDA approved. For new treatments and therapies to receive FDA approval, the investigational product must pass through four different phases: Phase 1, Phase 2 and Phase 3, are pre-FDA approval, while Phase 4 is considered post-FDA approval. DHAT Research Institute participates in all four Phases, 1 through 4, with our primary focus in Phase 2 and Phase 3 of the clinical research testing phase."

During the past decade, DHAT Research Institute conducted 23 clinical trials. In the 10-year time frame, 23 clinical trials started and 12 clinical trials were completed, i.e. on average, 52.2% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 12 clinical trials were completed. i.e. 171.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "DHAT Research Institute" #1 sponsor was "Shire" with 5 trials, followed by "Galapagos NV" with 3 trials sponsored, "Enanta Pharmaceuticals, Inc" with 2 trials sponsored, "Gilead Sciences" with 2 trials sponsored and "Janssen Research & Development, LLC" with 2 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "DHAT Research Institute" #1 collaborator was "Gilead Sciences" with 3 trials as a collaborator, "Galapagos NV" with 2 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator, "ICON Clinical Research" with 1 trials as a collaborator and "Triangle Biostatistics" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "DHAT Research Institute" are "Ulcerative Colitis" (7 trials), "Crohn's Disease" (6 trials), "Colitis, Ulcerative" (2 trials), "Non-Alcoholic Steatohepatitis" (2 trials) and "Crohn Disease" (1 trials). Many other conditions were trialed in "DHAT Research Institute" in a lesser frequency.

Most popular intervention types in "DHAT Research Institute" are "Drug" (21 trials), "Other" (4 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "Filgotinib" (5 trials), "Ontamalimab" (4 trials), "Etrasimod" (2 trials) and "Placebo to match filgotinib" (2 trials). Other intervention names were less common.

The vast majority of trials in "DHAT Research Institute" are 22 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "DHAT Research Institute". undefined are not yet recruiting, 2 are recruiting, 6 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 9 completed trials in DHAT Research Institute, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in DHAT Research Institute, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".